Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer

• Published in: Cancer research and treatment 2023, 55(3), , pp.814-831
• Main Authors: Liao, Rongxin, Chen, Kehong, Li, Jinjin, He, Hengqiu, Yi, Guangming, Huang, Mingfeng, Chen, Rongrong, Shen, Lu, Zhang, Xiaoyue, Xu, Zaicheng, Yang, Zhenzhou, Peng, Yuan
• Format: Article
• Language: English
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; DNA Helicases - genetics; Genomics - methods; High-Throughput Nucleotide Sequencing; Humans; Kelch-Like ECH-Associated Protein 1 - genetics; Lung Neoplasms - drug therapy; Mutation; NF-E2-Related Factor 2 - genetics; NF-E2-Related Factor 2 - therapeutic use; Nuclear Proteins - genetics; Original; Transcription Factors - genetics; 의학일반
• ISSN: 1598-2998; 2005-9256
• DOI: 10.4143/crt.2022.1315

Oligometastatic non-small cell lung cancer (NSCLC) patients have been increasingly regarded as a distinct group that could benefit from local treatment to achieve a better clinical outcome. However, current definitions of oligometastasis are solely numerical, which are imprecise because of ignoring the biological heterogeneity caused by genomic characteristics. Our study aimed to profile the molecular alterations of oligometastatic NSCLC and elucidate its potential difference from polymetastasis. We performed next-generation sequencing to analyze tumors and paired peripheral blood from 77 oligometastatic and 21 polymetastatic NSCLC patients to reveal their genomic characteristics and assess the genetic heterogeneity. We found ERBB2, ALK, MLL4, PIK3CB, and TOP2A were mutated at a significantly lower frequency in oligometastasis compared with polymetastasis. EGFR and KEAP1 alterations were mutually exclusive in oligometastatic group. More importantly, oligometastasis has a unique significant enrichment of apoptosis signaling pathway. In contrast to polymetastasis, a highly enriched COSMIC signature 4 and a special mutational process, COSMIC signature 14, were observed in the oligometastatic cohort. According to OncoKB database, 74.03% of oligometastatic NSCLC patients harbored at least one actionable alteration. The median tumor mutation burden of oligometastasis was 5.00 mutations/Mb, which was significantly associated with smoking, DNA damage repair genes, TP53 mutation, SMARCA4 mutation, LRP1B mutation, ABL1 mutation. Our results shall help redefine oligometastasis beyond simple lesion enumeration that will ultimately improve the selection of patients with real oligometastatic state and optimize personalized cancer therapy for oligometastatic NSCLC.